Trending...
- Don Barnhart's "Unapologetically Funny" Comedy Tour Keeps Las Vegas Laughing With 50% Discount
- Indie Brand Vow Beauty Enters Walmart
- HOPE Sheds Light to unveil new Manasquan location
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) unanimously voted to include VAXNEUVANCETM (Pneumococcal 15-valent Conjugate Vaccine) as a recommended option for vaccination in infants and children, including routine use in children under 2 years of age. Specifically, the ACIP voted to recommend that VAXNEUVANCE may be used as an option to the currently available 13-valent pneumococcal conjugate vaccine (PCV13) for children aged under 19 years according to currently recommended PCV13 dosing and schedules. Additionally, the ACIP unanimously voted to include VAXNEUVANCE in the Vaccines for Children program.
These provisional recommendations will be reviewed by the director of the CDC and the Department of Health and Human Services, and final recommendations will become official when published in the CDC's Morbidity and Mortality Weekly Report (MMWR).
VAXNEUVANCE is indicated for active immunization for the prevention of invasive disease caused by the Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in individuals 6 weeks of age and older. VAXNEUVANCE is contraindicated for individuals with a severe allergic reaction (e.g., anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid. See additional Select Safety Information for VAXNEUVANCE below.
"VAXNEUVANCE includes key serotypes that continue to cause serious disease in children under 5 years of age, specifically the 13 serotypes shared with PCV13, and the two unique serotypes, 22F and 33F. Serotypes 3, 22F and 33F are responsible for more than a quarter of all invasive pneumococcal disease cases in children. Today's vote reinforces the importance of VAXNEUVANCE as an option to help reduce the burden of invasive disease in the pediatric population," said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. "We applaud the ACIP and the CDC for their continued efforts to address invasive pneumococcal disease in children, and look forward to its final, published recommendations."
Select Safety Information for VAXNEUVANCE for infants and children
Do not administer VAXNEUVANCE to individuals with a severe allergic reaction (e.g., anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.
Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.
Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant's medical status and the potential benefits and possible risks.
The most commonly reported solicited adverse reactions in children vaccinated with a four-dose series at 2, 4, 6, and 12 through 15 months of age, provided as a range across the series, were: irritability (57.3% to 63.4%), somnolence (24.2% to 47.5%), injection-site pain (25.9% to 40.3%), fever ≥38.0°C (13.3% to 20.4%), decreased appetite (14.1% to 19.0%), injection-site induration (13.2% to 15.4%), injection-site erythema (13.7% to 21.4%) and injection-site swelling (11.3% to 13.4%).
More on Jersey Desk
The most commonly reported solicited adverse reactions in children and adolescents 2 through 17 years of age vaccinated with a single dose were: injection-site pain (54.8%), myalgia (23.7%), injection-site swelling (20.9%), injection-site erythema (19.2%), fatigue (15.8%), headache (11.9%) and injection-site induration (6.8%).
Vaccination with VAXNEUVANCE may not protect all vaccine recipients.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
More on Jersey Desk
This news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2021 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).
Please see Prescribing Information for VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) at https://www.merck.com/product/usa/pi_circulars/v/vaxneuvance/vaxneuvance_pi.pdf and Patient Information/Medication Guide for VAXNEUVANCE at https://www.merck.com/product/usa/pi_circulars/v/vaxneuvance/vaxneuvance_ppi.pdf.
Contacts
Media Contacts:
Julie Cunningham
(617) 519-6264
Kimberly Petrillo
(267) 742-2813
Investor Contacts:
Peter Dannenbaum
(908) 740-1037
Alexis Constantine
(908) 740-1051
These provisional recommendations will be reviewed by the director of the CDC and the Department of Health and Human Services, and final recommendations will become official when published in the CDC's Morbidity and Mortality Weekly Report (MMWR).
VAXNEUVANCE is indicated for active immunization for the prevention of invasive disease caused by the Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in individuals 6 weeks of age and older. VAXNEUVANCE is contraindicated for individuals with a severe allergic reaction (e.g., anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid. See additional Select Safety Information for VAXNEUVANCE below.
"VAXNEUVANCE includes key serotypes that continue to cause serious disease in children under 5 years of age, specifically the 13 serotypes shared with PCV13, and the two unique serotypes, 22F and 33F. Serotypes 3, 22F and 33F are responsible for more than a quarter of all invasive pneumococcal disease cases in children. Today's vote reinforces the importance of VAXNEUVANCE as an option to help reduce the burden of invasive disease in the pediatric population," said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. "We applaud the ACIP and the CDC for their continued efforts to address invasive pneumococcal disease in children, and look forward to its final, published recommendations."
Select Safety Information for VAXNEUVANCE for infants and children
Do not administer VAXNEUVANCE to individuals with a severe allergic reaction (e.g., anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.
Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.
Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant's medical status and the potential benefits and possible risks.
The most commonly reported solicited adverse reactions in children vaccinated with a four-dose series at 2, 4, 6, and 12 through 15 months of age, provided as a range across the series, were: irritability (57.3% to 63.4%), somnolence (24.2% to 47.5%), injection-site pain (25.9% to 40.3%), fever ≥38.0°C (13.3% to 20.4%), decreased appetite (14.1% to 19.0%), injection-site induration (13.2% to 15.4%), injection-site erythema (13.7% to 21.4%) and injection-site swelling (11.3% to 13.4%).
More on Jersey Desk
- Craft Data System Sets To Address Teacher Shortages Nationwide With a TurnKey On-The-Job, Low-Cost Degrees Model and Platform
- Dr. Kimbi Marenakos Launches New App, "Burnout Breakthrough" to Defeat the Burnout Epidemic
- Atrium Management Company Merges with Richmond-based Dodson Multi-Family
- "Shutup Springsteen" Released! New Video & Single By Gary Frost - Country Artist & New Jersey Native
- #SIDEGIGCON 2022 Teaches How to Recession-Proof Lifestyles with Side Gigs
The most commonly reported solicited adverse reactions in children and adolescents 2 through 17 years of age vaccinated with a single dose were: injection-site pain (54.8%), myalgia (23.7%), injection-site swelling (20.9%), injection-site erythema (19.2%), fatigue (15.8%), headache (11.9%) and injection-site induration (6.8%).
Vaccination with VAXNEUVANCE may not protect all vaccine recipients.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
More on Jersey Desk
- Faropoint Sells Portfolio of 109 Institutional-Quality Last-Mile Warehouses For $481M
- Designer Ivey Abitz Empowers Women with Joyful History Inspired Collection
- FCTI, Inc. Brings Aboard Bennett Robinson as New Vice President of Finance
- Morgan Seamark Joins Triggers® Brand Consulting As Managing Director
- Group for LGBTQ+ Adults with Developmental Disabilities to Hold Virtual Meeting on July 19, 7pm. New Members Welcome
This news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2021 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).
Please see Prescribing Information for VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) at https://www.merck.com/product/usa/pi_circulars/v/vaxneuvance/vaxneuvance_pi.pdf and Patient Information/Medication Guide for VAXNEUVANCE at https://www.merck.com/product/usa/pi_circulars/v/vaxneuvance/vaxneuvance_ppi.pdf.
Contacts
Media Contacts:
Julie Cunningham
(617) 519-6264
Kimberly Petrillo
(267) 742-2813
Investor Contacts:
Peter Dannenbaum
(908) 740-1037
Alexis Constantine
(908) 740-1051
Filed Under: Business
0 Comments
Latest on Jersey Desk
- GARP CEO Richard Apostolik Delivers Keynote Address at China ESG Investment and Development Forum
- Don Barnhart's "Unapologetically Funny" Comedy Tour Keeps Las Vegas Laughing With 50% Discount
- Craig W Brearley Architecture Transitions to New Ownership While Maintaining a Tradition of Architec
- Curio Digital Therapeutics Partners with Axia Women's Health To Support Patients with Postpartum Depression
- Damco Solutions Delivers a Web Portal for Minting, Buying, and Selling NFTs
- Best Cocktails and Bar Food in Astoria, Queens
- Nye & Company's next Chic and Antique Estate Treasures Auction will be held on Wednesday, July 20th
- Church & Dwight to Webcast Discussion of Second Quarter 2022 Results on July 29
- How Massage Therapy Near You Frees Your Body Of Pain So You Move Better, Sleep Better, Feel Better, Without Back Pain, Neck Pain, Headaches, And More!
- Nasal obstruction? VivAer® might be the answer
- Jerry W. Conaty named Chair of the NJCPA's Governmental Accounting and Audit Interest Group
- Celebrate New Jersey By Sharing Your Favorite Summer Places
- InventHelp Inventor Develops Safe/Social Distance Desk for Students (HBR-125)
- Rook Coffee Is Bringing Back Your Favorite Summer Treat
- Merck to Hold Second-Quarter 2022 Sales and Earnings Conference Call July 28
- New Factbook Delivers First Reference Compilation for 2022 Russia-Ukraine War
- B&G Foods Announces Credit Agreement Amendment
- Mutual Aid Ambulance Service Partners with Excela Health for Paramedic Training Program
- Carluccio, Leone, Dimon, Doyle & Sacks, LLC welcomes Jennifer S. Weiss as Civil Litigation Attorney
- In2Scuba Diving Co. of Maui introduces its exclusive beginner scuba diving lessons